As per the recently published report by MarketsandMarkets™, The report “Organ-On-Chip Market by Organ Type (Liver, Kidney, Intestine, Lung, Heart), Products (Instruments, Consumable, Software), Services (Standard, Custom), Model Type, Application (Toxicology, Drug Discovery, Stem Cell), Purpose – Global Forecast to 2029″, is expected reach USD 631,073 thousand by 2029 from USD 123,285 thousand in 2024, at a CAGR of 38.6% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144117291
 
Browse

• 396     Market Data Tables
• 38       Figures
• 353     Pages and in-depth TOC on “ Organ-On-Chip Market – Global Forecast to 2029”

Some of the prominent key players are:

• MIMETAS B.V. (Netherlands),
• TissUse GmBH (Germany),
• Netri (France),
• Emulate, Inc. (US),
• CN Bio Innovations Ltd (UK),
• Insphero AG (Switzerland),
• SynVivo, Inc. (US), and many more……

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Organ-On-Chip Market.

Growth Driver: Increasing demand for animal free testing and growing government and private institution funding

Organ-on-chip technology is being developed as a potential substitute to animal drug testing. Often drugs in the final stages of pre clinical trials fail due to differences in animal and human physiology and drug metabolism. This high attrition of potential drug candidates and ethical concerns regarding use of animal for drug testing has lead to development of organ-on-chip technology reduce reliance on animals and to improve drug toxicity testing efficacy. Use of animals for testing of cosmetic drugs is banned in Europe since 2013. In 2023, the US FDA passed Modernization Act 2.0 to reduce animal drug testing and rely on alternative drug testing methods such as organ-on-chips.

Market Segmentation: –

• Among the model type subsegments, the market is segmented organ-based model and disease-based models. In 2023, the disease-based model segment accounted for the highest growth rate in the organ-on-chip market by model type. The high growth of this segment can be attributed to the growing adoption of disease based models for progressing studies associated with several conditions along with an application of these models in personalized medicine development.
• Among the organ type subsegment, the organ-on-chip market is segmented into liver, kidney, lung, heart, intestine and other organs. In 2023, liver-on-chip segment accounted for the fastest-growing market of the organ type segment of organ-on-chip market. The high growth of this market segment can be attributed to the growing focus on animal-free drug discovery and development methods and increasing preclinical research to evaluate drug hepatotoxicity
• The European market is the second-largest organ-on-chip market globally, mainly due to factors such as advancements in biofabrication technology and use of artificial intelligence in drug discovery and testing. The increased collaboration and partnership between private companies and government institutes along with increased awareness of the organ-on-chip technology are other important factors responsible for the size of the market.

Opportunity: Development of multi-organ-on-chip systems

Muti-organ-on-chip systems are developed the functions of multiple organs and inter-organ communications enabling study of drug responses and evaluate drug toxicity for various organs simultaneously. Multi-organ chips (MOCs) are used for safety assessments in the cosmetic and food industries, providing a animal free and efficient compound testing methods. In cosmetics, miniaturized versions of human skin, eyes, and relevant organs, allow for safety evaluations of ingredients and finished products without animal testing. MOCs can be developed with individual specific cells allowing companies to assess interaction of specific compounds with unique skin biology. MOCs incorporating digestive organs allow evaluation of nutrients to develop personalized and nutritious food products. These chips also offer a alternative approach to toxicity testing, replacing traditional animal models.

Recent Developments of Organ-on-Chip Industry:

• In September 2023, CN Bio Innovations Ltd (UK) and LifeNet Health LifeSciences (US) partnered to provide validated human cells for CN Bio’s Organ-on-a-Chip systems.  
• In June 2023 TissUse GmbH (Germany) and PMI (US) entered a collaborative agreement to leverage PMI’s InHALES technology along with TissUse’s Multi-Organ-Chip (MOC) platform. 

Growth in the organ-on-chip market can mainly be attributed to the increasing government initiatives to reduce drug testing on animal models. Additionally, factors such as advancements in biofabrication technologies and greater acceptance of organ-on-chip technology by pharma and biotechnology companies also contributes to the growth of this market. However, technical complexities of the organ-on-chip models along with low throughput of current organ-on-chip technology pose challenge for the market growth to a certain extent. 

Related News :-https://www.prnewswire.com/news-releases/organ-on-chip-market-worth-631-073-thousand–marketsandmarkets-302067265.html